SAB Biotherapeutics (SABS) Cash & Equivalents (2020 - 2026)

SAB Biotherapeutics (SABS) has 7 years of Cash & Equivalents data on file, last reported at $20.5 million in Q1 2026.

• Quarterly Cash & Equivalents rose 263.8% year-over-year to $20.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.5 million (up 263.8% YoY) and the FY2025 annual result came in at $10.5 million, up 18.03% from the prior year.
• Cash & Equivalents climbed to $20.5 million in Q1 2026, from $10.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $56.6 million in Q4 2023 to a low of $2.4 million in Q3 2023.
• A 5-year average of $15.4 million and a median of $13.1 million in 2023 frame the typical range for Cash & Equivalents.
• The widest YoY moves for Cash & Equivalents: up 278.12% in 2024, down 84.27% in 2024.
• Tracing SABS's Cash & Equivalents over 5 years: stood at $15.0 million in 2022, then surged by 275.93% to $56.6 million in 2023, then sank by 84.27% to $8.9 million in 2024, then gained by 18.03% to $10.5 million in 2025, then jumped by 95.38% to $20.5 million in 2026.
• The last three Cash & Equivalents figures came in at $20.5 million (Q1 2026), $10.5 million (Q4 2025), and $29.4 million (Q3 2025), per Business Quant data.